Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors.
intratumoral therapy
monoclonal antibodies (mAbs)
non-viral therapy
viral therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Jan 2023
31 Jan 2023
Historique:
received:
22
12
2022
revised:
27
01
2023
accepted:
28
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Immunotherapies based on immune checkpoint blockade have shown remarkable clinical outcomes and durable responses in patients with many tumor types. Nevertheless, these therapies lack efficacy in most cancer patients, even causing severe adverse events in a small subset of patients, such as inflammatory disorders and hyper-progressive disease. To diminish the risk of developing serious toxicities, intratumor delivery of monoclonal antibodies could be a solution. Encouraging results have been shown in both preclinical and clinical studies. Thus, intratumor immunotherapy as a new strategy may retain efficacy while increasing safety. This approach is still an exploratory frontier in cancer research and opens up new possibilities for next-generation personalized medicine. Local intratumor delivery can be achieved through many means, but an attractive approach is the use of gene therapy vectors expressing mAbs inside the tumor mass. Here, we summarize basic, translational, and clinical results of intratumor mAb delivery, together with descriptions of non-viral and viral strategies for mAb delivery in preclinical and clinical development. Currently, this is an expanding research subject that will surely play a key role in the future of oncology.
Identifiants
pubmed: 36768997
pii: ijms24032676
doi: 10.3390/ijms24032676
pmc: PMC9917067
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Pharm Sci. 2020 Jan;109(1):74-103
pubmed: 31173761
J Control Release. 2021 Jun 10;334:389-412
pubmed: 33964364
Front Oncol. 2019 Feb 14;9:52
pubmed: 30838171
Curr Oncol Rep. 2020 Mar 21;22(4):39
pubmed: 32200442
Biomedicines. 2014 Feb 21;2(1):36-49
pubmed: 28548059
Proc Biol Sci. 2015 Dec 22;282(1821):20143003
pubmed: 26702034
Ann Oncol. 2018 Nov 1;29(11):2163-2174
pubmed: 30295695
Curr Opin Pharmacol. 2012 Oct;12(5):615-22
pubmed: 22920732
Nat Nanotechnol. 2019 Jan;14(1):89-97
pubmed: 30531990
Front Oncol. 2020 Jul 23;10:1182
pubmed: 32793488
Oncotarget. 2018 Feb 6;9(17):13623-13636
pubmed: 29568382
Oncoimmunology. 2015 Aug 12;5(2):e1074374
pubmed: 27057439
Biomedicines. 2020 Dec 02;8(12):
pubmed: 33276580
MAbs. 2021 Jan-Dec;13(1):1860476
pubmed: 33459118
Biomedicines. 2019 Aug 30;7(3):
pubmed: 31480379
Front Cell Neurosci. 2014 Oct 21;8:344
pubmed: 25374510
Vaccine. 2021 Jan 8;39(2):197-201
pubmed: 33279318
Int J Cancer. 2019 Sep 1;145(5):1189-1199
pubmed: 30664811
J Cutan Pathol. 2021 May;48(5):674-679
pubmed: 33399228
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Immunol Lett. 2021 Dec;240:137-148
pubmed: 34710507
Theranostics. 2022 Jan 31;12(5):1999-2014
pubmed: 35265195
EMBO Mol Med. 2011 Oct;3(10):581-92
pubmed: 21739608
BioDrugs. 2018 Oct;32(5):425-440
pubmed: 30043229
Cancer Res. 2006 Feb 1;66(3):1620-9
pubmed: 16452221
Drug Dev Ind Pharm. 2002 Jan;28(1):1-13
pubmed: 11858519
Cancers (Basel). 2022 Sep 14;14(18):
pubmed: 36139625
Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):107-19
pubmed: 20143172
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Ann Oncol. 2010 Aug;21(8):1712-1717
pubmed: 20147741
Pharmacol Res Perspect. 2019 Dec;7(6):e00535
pubmed: 31859459
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32571995
Br J Cancer. 2022 May;126(8):1168-1177
pubmed: 34969998
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Acc Chem Res. 2022 Jan 4;55(1):2-12
pubmed: 34850635
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
J Control Release. 2022 Sep;349:143-155
pubmed: 35508223
Mol Ther Methods Clin Dev. 2020 Jun 18;18:402-414
pubmed: 32695842
Nat Rev Genet. 2020 Apr;21(4):255-272
pubmed: 32042148
J Virol. 2020 Jan 17;94(3):
pubmed: 31694938
J Immunother Cancer. 2021 Dec;9(12):
pubmed: 34949694
Cancer Immunol Res. 2020 May;8(5):632-647
pubmed: 32127389
Int J Mol Sci. 2022 Aug 29;23(17):
pubmed: 36077216
BioDrugs. 2020 Feb;34(1):11-26
pubmed: 31686399
Bioorg Med Chem. 2018 Jun 1;26(10):2700-2707
pubmed: 28720325
Mol Ther. 2020 Mar 4;28(3):723-746
pubmed: 31972133
J Mater Chem B. 2021 Mar 21;9(11):2561-2583
pubmed: 33599653
Am J Manag Care. 2018 Feb;24(2):109-112
pubmed: 29461857
J Clin Oncol. 2020 Aug 10;38(23):2667-2676
pubmed: 32552274
Mol Biol Rep. 2021 Sep;48(9):6563-6580
pubmed: 34424444
Cancers (Basel). 2022 Aug 09;14(16):
pubmed: 36010840
Front Immunol. 2020 May 29;11:627
pubmed: 32547534
Oncoimmunology. 2014 Jul 03;3(7):e945378
pubmed: 25954597
Mol Ther Nucleic Acids. 2022 Jul 20;29:387-399
pubmed: 36035753
Cancers (Basel). 2020 Oct 15;12(10):
pubmed: 33076303
Curr Med Chem. 2020;27(16):2631-2657
pubmed: 31755377
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Acc Chem Res. 2017 Apr 18;50(4):680-690
pubmed: 28248486
J Virol. 2010 Jun;84(11):5627-36
pubmed: 20237085
ACS Nano. 2016 Sep 27;10(9):8956-63
pubmed: 27599066
Virus Res. 2010 Nov;153(2):179-96
pubmed: 20692305
Hum Gene Ther. 2019 Nov;30(11):1431-1443
pubmed: 31382777
Adv Mater. 2018 May;30(22):e1707112
pubmed: 29656492
Nat Rev Cancer. 2015 Jun;15(6):361-70
pubmed: 25998715
J Nanosci Nanotechnol. 2015 Jan;15(1):41-53
pubmed: 26328304
Nano Lett. 2016 Apr 13;16(4):2334-40
pubmed: 26999507
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Semin Immunol. 2021 Feb;52:101425
pubmed: 33272897
Vaccines (Basel). 2013 Jun 25;1(3):225-49
pubmed: 26344110
Life Sci. 2022 Apr 1;294:120375
pubmed: 35123997
Br J Pharmacol. 2009 May;157(2):220-33
pubmed: 19459844
Cancer Immunol Res. 2015 May;3(5):449-54
pubmed: 25691326
Mol Ther Methods Clin Dev. 2017 Sep 20;7:74-82
pubmed: 29034261
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4025-4030
pubmed: 30765520
JCI Insight. 2018 Jun 21;3(12):
pubmed: 29925692
Cancer Gene Ther. 2022 Jul;29(7):984-992
pubmed: 34754076
Genome Med. 2019 Jun 20;11(1):39
pubmed: 31221204
Adv Drug Deliv Rev. 2020;165-166:41-59
pubmed: 31837356
Cells. 2022 Jul 30;11(15):
pubmed: 35954196
Curr Pharm Des. 2019;25(13):1443-1454
pubmed: 31258071
Int J Mol Sci. 2021 Apr 03;22(7):
pubmed: 33916696
Int J Mol Sci. 2020 Aug 18;21(16):
pubmed: 32824655
Mol Ther. 2019 Nov 6;27(11):1892-1905
pubmed: 31563534
J Transl Med. 2017 Jun 7;15(1):131
pubmed: 28592330
Annu Rev Virol. 2019 Sep 29;6(1):601-621
pubmed: 31283441
NPJ Precis Oncol. 2022 Jun 21;6(1):42
pubmed: 35729210
J Control Release. 2018 Sep 28;286:301-314
pubmed: 30077735
Mol Ther. 2019 Apr 10;27(4):710-728
pubmed: 30846391
Cancer Immunol Res. 2014 Mar;2(3):229-40
pubmed: 24778319
J Hematol Oncol. 2020 Jun 29;13(1):84
pubmed: 32600470
J Immunother Cancer. 2019 May 2;7(1):116
pubmed: 31046839
Mol Ther. 2005 Jul;12(1):153-63
pubmed: 15963931
J Gen Virol. 1999 Jan;80 ( Pt 1):131-136
pubmed: 9934695
Gene Ther. 2005 Aug;12(16):1253-63
pubmed: 15944731
Theranostics. 2019 Sep 21;9(23):6867-6884
pubmed: 31660074
Clin Cancer Res. 2020 Jul 1;26(13):3091-3099
pubmed: 32071116
Int J Mol Sci. 2021 Apr 17;22(8):
pubmed: 33920699
EMBO Mol Med. 2019 Jul;11(7):e10293
pubmed: 31273938
Front Immunol. 2017 Nov 22;8:1603
pubmed: 29213270
Chest. 1988 Oct;94(4):676-8
pubmed: 3168562
Clin Cancer Res. 2018 Nov 15;24(22):5552-5561
pubmed: 30045932
J Clin Oncol. 2010 Oct 1;28(28):4324-32
pubmed: 20697067
Nat Commun. 2019 Aug 28;10(1):3850
pubmed: 31462642
Mol Ther. 2020 Apr 8;28(4):1068-1077
pubmed: 32101701
J Virol. 2006 Nov;80(21):10900-6
pubmed: 16928748
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910
Acc Chem Res. 2020 Nov 17;53(11):2521-2533
pubmed: 33073988
Nat Commun. 2017 Mar 02;8:14630
pubmed: 28251988
Cell Rep. 2017 Aug 22;20(8):1818-1829
pubmed: 28834746
Clin Cancer Res. 2021 Feb 1;27(3):665-679
pubmed: 32943460
Theranostics. 2019 Apr 12;9(8):2299-2314
pubmed: 31149045
Cancers (Basel). 2020 Feb 04;12(2):
pubmed: 32033028
Signal Transduct Target Ther. 2022 Feb 7;7(1):39
pubmed: 35132063